1-9 of 9
Anke Schilhabel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Clinical Trials & Observations
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2024) 144 (3): 272–282.
https://doi.org/10.1182/blood.2023022730
Published: 2024
Includes: Supplemental data
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Anke Schilhabel, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Eugen Tausch, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Marinus H.J. Van Oers, Caspar Da Cunha-Bang, Christian H. Geisler, Stephan Stilgenbauer, Monika Brüggemann, Michael Hallek, Matthias Ritgen, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 72.
https://doi.org/10.1182/blood-2021-147729
Published: 2021
Journal Articles

Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL

Mouhamad Khouja, Anke Schilhabel, Michaela Kotrova, Monika Brüggemann, Christian Kuffer, Derek Blair, Nikos Darzentas, Christiane Pott
Journal: Blood
Blood (2021) 138 (Supplement 1): 3498.
https://doi.org/10.1182/blood-2021-153176
Published: 2021
Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Clinical Trials & Observations
Moritz Fürstenau, Anna Maria Fink, Anke Schilhabel, Jonathan Weiss, Sandra Robrecht, Robert Eckert, Javier de la Serna, Marta Crespo, Marta Coscia, Candida Vitale, Sebastian Böttcher, Gesche Weppner, Matthias Ritgen, Stephan Stilgenbauer, Eugen Tausch, Kirsten Fischer, Michael Hallek, Barbara Eichhorst, Monika Brüggemann, Carmen D. Herling
Journal: Blood
Blood (2021) 137 (16): 2267–2271.
https://doi.org/10.1182/blood.2020008609
Published: 2021
Includes: Supplemental data
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
https://doi.org/10.1182/blood-2019-125825
Published: 2019
Journal Articles

Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials

Anke Schilhabel, Henrik Knecht, Anton W. Langerak, Jacques J.M. van Dongen, Michael Kneba, Jill Ray, Elizabeth Punnoose, Doris Kim, Thomas Haberberger, Coen Bernaards, Yuda Zhu, Sock-Cheng Lewin-Koh, Matthias Ritgen
Journal: Blood
Blood (2015) 126 (23): 2924.
https://doi.org/10.1182/blood.V126.23.2924.2924
Published: 2015